BOSTON, Nov. 19, 2019 /PRNewswire/ -- Elucidata, a
disruptive integrated Omics company that uses their proprietary
AI-enabled technology PollyTM Discover to assist in
asset discovery, announced today the formation of a Scientific
Advisory Board (SAB). The board will include Dr. Richard Kibbey MD/PhD, Elucidata's Scientific
Co-Founder, Dr. Nick Pullen, PhD,
and Dr. Avi Ma'ayan, PhD.
"We are thrilled to have Dr. Pullen and Dr. Ma'ayan join our
Scientific Advisory Board," said Dr. Abhishek Jha, PhD, Chief Executive Officer,
Elucidata. "Their leadership will help us expand the reach of our
asset discovery offering, PollyTM Discover, and will
power further innovation by breaking barriers in using biomedical
data to drive decisions."
Chaired by Dr. Pullen, the SAB will bring together the expertise
of scientists from the fields of drug discovery and computational
biology. The SAB will work closely with Elucidata's leadership to
advance PollyTM Discover, particularly focusing on
the roadmap and go-to-market strategy.
Dr. Pullen brings more than 20 years of experience working in
the pharmaceutical industry with Pfizer, Roche and, more recently,
Celgene. He has significant expertise in target identification and
the prosecution of drug discovery programs from idea to clinical
proof of mechanism, across broad disease, target and physiological
systems.
"The Discovery playbook just keeps getting larger and
PollyTM Discover has proven to be an exceptionally
useful offering in de-convoluting large multi-parametric datasets
for the purposes of target and biomarker discovery, as well as
optimizing the potential of engineered cellular therapies," said
Dr. Pullen. "Realizing its broadest application, in conjunction
with the expertise in Elucidata is the key goal of the SAB."
Dr. Ma'ayan is the Director of the Mount Sinai Center for
Bioinformatics and an Endowed Professor of Bioinformatics in the
Department of Pharmacological Sciences. Dr. Ma'ayan is also the
Principal Investigator of the NIH-funded BD2K-LINCS Data
Coordination and Integration Center and Mount Sinai Knowledge
Management Center for Illuminating the Druggable Genome.
"This is an exciting time in biomedical research. We will see a
shift toward data driven science which undoubtedly will accelerate
target, drug discovery and new therapeutics development. Elucidata
brings great expertise, innovation and energy into this emerging
field," added Dr. Ma'ayan.
"Elucidata has created a transformative offering,
PollyTM Discover to free brilliant scientists for
creative innovation rather than the mind-numbing and menial
trudging through piles of raw data," said Dr. Kibbey. "There is so
much 'unused' biologic Omic data out there. It is so rewarding to
be in a position to capture, interpret, integrate and translate
into potential therapies the already amassed troves of data, let
alone the anticipated exponential explosion as next generation
technologies emerge."
Dr. Kibbey is a clinically active Associate Professor of
Medicine (Endocrinology) and of Cellular & Molecular Biology at
the Yale School of Medicine. He heads
an independent NIH-supported laboratory studying whole-body and
subcellular metabolism in the context of diabetes and cancer.
About Elucidata Corporation
Elucidata was founded in
2015 with a mandate to transform the way biomedical data is used to
drive decisions in R&D labs in both academia and industry.
Elucidata's long-term goal is to use artificial intelligence to
enable the discovery of assets. Elucidata has offices in
Cambridge, MA, San Francisco, CA and New Delhi, India.
About PollyTM Discover
PollyTM
Discover is Elucidata's AI-enabled technology for the integration
of biomedical data to enable translational researchers to discover
therapeutic assets. PollyTM Discover combines
disease-specific highly curated data lakes with proprietary ML
frameworks to enable faster and better discovery of assets.
Contact
Joshua Milne,
Joshua Milne PR, 229451@email4pr.com, 617-501-1620
View original
content:http://www.prnewswire.com/news-releases/elucidata-announces-formation-of-scientific-advisory-board-300960376.html
SOURCE Elucidata